CD47 and neoplasm: These antagonists include 1) monoclonal antibodies targeting CD47 or SIRPα, 2) SIRPα-Fc fusion proteins, 3) bispecific antibodies (BsAb), 4) small molecules to down-regulate CD47 on tumor cells, 5) RNAi and, 6) CD47-chimeric antigen receptor-T cell/Macrophages.